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“  Kids are different today, I hear every mother say  
Mother needs something today to calm her down  
And though she’s not really ill, there’s a little yellow pill  
She goes running for the shelter of her mother’s little helper  
And it helps her on her way, gets her through her busy day…”
 
—Mother’s Little Helper, The Rolling Stones 
3
Foreword
In this edition of Prevention Research, our 
attention is focussed on two pharmaceutical 
drugs causing the most harm; opioid analgesics, 
(used to treat pain), including codeine; and 
benzodiazepines, including Valium®, used to 
treat stress, anxiety and insomnia. Both types 
of drugs are generally only recommended for 
short-term use, but they are commonly being 
used for long periods of time in Australia. 
At the Alcohol and Drug Foundation, we 
believe pharmaceutical misuse is Australia’s 
fastest-growing drug problem. The number 
of people dying after taking codeine has 
doubled in the past decade (1). More people 
die from overdosing on pharmaceuticals than 
all illicit drugs combined (2), and this number 
is overtaking the national road toll (3). These 
deaths may also in part be linked to our alcohol 
culture, as many are caused by mixing 
medication with alcohol (4) (1). In Australia 
5,500 people die from misuse of alcohol 
every year and 170,000 are hospitalised (5).
Pharmaceutical drugs are legitimately relied 
on by most people at some point in their life 
to cope with pain and fight infection and 
disease. Yet overuse of medication can result 
in severe problems, including exacerbating the 
very negative feelings and symptoms they are 
designed to lessen. Sometimes this overuse 
can lead to drug dependence and overdose.  
As the same pharmaceuticals can be a friend  
or a foe, depending on the circumstances, 
it is vital that Australians have a clear 
understanding of the risks and benefits 
of using these medications. 
 Our interest, at the Alcohol and Drug 
Foundation, lies in promoting the safest use 
of pharmaceutical drugs in order to avoid 
preventable problems and harms. 
That includes developing an understanding 
within the whole community that for many 
difficult conditions — including chronic pain, 
stress, anxiety and insomnia — there are 
alternatives to medication that don’t have 
negative side effects. These include counselling, 
relaxation and mindfulness techniques, exercise 
and changes in diet and lifestyle. 
As a society we need to look at safe and 
effective ways people can manage and recover 
from health issues without creating further  
— and sometimes fatal — harms.
I trust this Prevention Research issue, ‘Is there 
a pill for that?’ will contribute to that end. 
John Rogerson,  
Alcohol and Drug Foundation CEO
When the Rolling Stones wrote the song ‘Mother’s Little Helper’ in 
1966 about the risks and benefits of prescribed sedatives, they were 
probably referring to Valium, a type of benzodiazepine. Valium® 
emerged a few years earlier and became wildly popular, even with 
the risk of dependence. Despite the name, in Australia today it is 
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Australians benefit from the 
availability of a wide range of 
pharmaceuticals, which can be 
effective in helping to manage a 
broad spectrum of health conditions. 
  However, opioids (both prescription and over-the-
counter)  and benzodiazepines (tranquilisers used 
to treat stress, anxiety and insomnia) are 
overused (6) and over prescribed (7). This is 
connected to rapidly increasing rates of drug 
dependency (8), severe injury (9) and death (10). 
Introduction
The number of people dying from 
pharmaceutical opioid drug overdoses in 
Australia has risen significantly over the past 10 
years and is now overtaking the national road 
toll. In Victoria alone, these drugs contributed to 
330 people dying from a drug overdose. This is 
higher than the state’s 2015 road toll [252] (11) 
and higher than overdoses from illegal drugs 
[217] and alcohol [97] (12) (2).
As an indicator of concern, Australia’s 
Therapeutic Goods Administration (TGA) 
recently cited increasing levels of codeine 
dependence and recommended that all over-
the-counter medicines containing codeine 
be rescheduled to become prescription-only 
medicines (13). From 1 February 2018, medicines 
that contain low-dose codeine will no longer be 
available in pharmacies without a prescription.  
(14) (15).
 This problem is not Australia’s alone. 
Other western countries, particularly the 
United States and Canada, report similar 
problems relating to pharmaceutical opioid 
and benzodiazepine use (16).
Governments, policymakers and researchers 
in Australia have been working to identify 
ways of addressing risks associated with 
the overuse and over-prescription of opioids 
and benzodiazepines in Australia before they 
escalate further. It’s clear that a multifaceted 
response is required. 
There is a range of evidence-based, alternative 
treatments for chronic pain, stress, anxiety and 
insomnia, and these don’t have the negative 
side effects associated with pharmaceuticals. 
These treatments include counselling including 
cognitive behavioural therapy, relaxation and 
mindfulness techniques, as well as diet changes 
and exercise. However, the uptake of these 
treatments is low, underfunded and often not 
considered or prescribed.   
Given the rising concern and evidence of high 
and increasing harms, this publication has been 
produced to help raise awareness of this issue, 
its complexities, and encourage conversation 




Opioids and benzodiazepines should only be used in 
the short term otherwise they can become harmful. 
Over time the drugs may stop working and extended 
use can increase the chances of negative side 
effects, including dependence (17) (18). 
Harmful use of 
pharmaceuticals 
Many Australians may believe pharmaceuticals 
are safe because they are legal drugs, and 
that medical guidance can be followed loosely. 
As a result, Australians may not be aware  
they are engaging in potentially harmful  
behaviour, including: 
  Taking more medication than prescribed 
or directed on the packet, either in one 
dose or over time.
  Taking medication in a different way 
to what’s recommended, such as snorting  
or injecting a medication that is meant for 
oral use. 
  Using medication without a prescription 
and ongoing medical supervision.
  Combining drugs, including alcohol, 
when it’s not recommended.
  Continuing with activities that medication 
affects, for example driving, working, 
looking after children.
  Sharing prescription medication 
with friends, family or colleagues.
The responsibility sits with both the doctor/ 
pharmacist to provide information and the 
consumer/patient to make sure they are clear 
about the guidance and follow it as directed  
to ensure that no harm is experienced. 
Some medication misuse is deliberate, for 
example when people take a pharmaceutical 
drug for a euphoric or other psychoactive 
effect. In 2013, over 200,000 adult Australians 
reported deliberately misusing over - the-counter 
codeine analgesics (19). 
  In these cases, people may source 
the codeine from a friend or family 
member, or via the Internet, in 






How big is  
the problem? 
In 2013, the number of Australians 
who had misused pharmaceuticals 
increased to 11.4 per cent.
Data from the Pharmaceutical Benefits Scheme 
(PBS), ambulance attendances, hospitalisations, 
coronial records and self-report surveys 
suggests pharmaceutical drug misuse is 
widespread and growing.
According to the National Drug Strategy 
Household Survey, pharmaceutical drug use 
rose significantly in 2013 (20).  In 2013, the  
number of Australians who had misused phar-
maceuticals increased to 11.4 per cent from 7.4 
per cent in 2010 (20) (21). Between 2010 and 
2013, the greatest increases occurred among 
males in their 30s and females in their 40s (20). 
The increase was larger for males than females 
across all pharmaceutical drug types (20).
Further statistics are given in the following section.
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To initiate change, 
Australians first 
need to understand 
the problem and its 
associated harms. 






the most harm 
Benzodiazepines 
Despite being commonly prescribed,  
evidence suggests that benzodiazepines 
are not the best treatment for stress, 
anxiety or insomnia, especially if the 
problem is likely to be ongoing. 
The risk of developing dependence on the drug is 
higher the longer it’s used. It generally shouldn’t 
be used for longer than two weeks (25). 
Benzodiazepines, or minor tranquilisers (see  
Table 1 for common brand names), are prescribed 
for managing stress, anxiety, and insomnia 
(24). Drug-use patterns in states and territories 
generally reflect national trends; in Victoria they 
contributed to over half of all pharmaceutical 
drug overdose deaths in 2015 (2).
As well as the risk of dependence, other 
side effects include drowsiness, depression, 
headaches, tiredness but difficulty sleeping, 
irritability, personality changes, impaired 
thinking, paranoia, reduced sex drive and 
fertility problems (17). More effective treatments, 
which also don’t have negative side effects, 
include counselling such as cognitive behavioural 
therapy, exercise and diet changes (25).
GENERIC NAME BRAND NAME TYPE OF BENZODIAZEPINE
Diazepam Ducene®, Valium® Long-acting
Oxazepam Alepam®, Murelax®, Serepax® Short-acting
Nitrazepam Alodorm®, Mogadon® Intermediate-acting
Temazepam Euhypnos®, Normison® Short-acting
Alprazolam Xanax®, Kalma®, Alprax® Short-acting
Table 1 Brand names adapted from Brands B, 
Sproule B, Marshman J, (1998) Drugs & Drug Abuse 






Codeine Other opioids Codeine (cont.)
Most painkillers, except paracetamol, 
are opioids similar to heroin.
Opioids help many Australians manage intense 
pain, for example after surgery or dental work, 
and are a key part of helping them to recover. 
However, they can have side effects includ-
ing drowsiness, constipation, muscle tension, 
headaches, and dental and stomach problems 
(18). They can also reduce sex drive and fertility, 
cause moodiness and fluid retention, decrease 
bone density and may cause dependence if 
used for extended periods of time (18).
The risk of experiencing these side effects  
is higher the longer they are used. Opioids  
may stop working on pain after they are used  
regularly for extended periods. Australians are 
increasingly using them for longer, even though 
the negative side effects generally outweigh the 
positive effects after an extended period of time.
Opioid-related hospitalisations increased from 
605 in 1998 to 1,464 in 2009, outnumbering all 
hospitalisations due to heroin poisoning since 
2001 (22). According to a survey of people
accessing needle and syringe program services 
in Australia, the proportion of respondents who 
reported last injecting pharmaceutical opioids 
has nearly doubled since 2001, peaking in 2010
at 16 per cent (26).
In 2012, more than two-thirds of the 564 acciden-
tal opioid deaths among Australians aged 15 to 
54 were due to pharmaceutical opioids (27).
Codeine is an opioid drug that is used to provide 
relief from a number of conditions including mild 
to moderate pain, severe pain (when combined 
with aspirin or paracetamol), dry irritating 
cough, diarrhoea and cold and  flu (when 
combined with antihistamines and deconges-
tants). (See Table 2 for common brand names.) 
More codeine is consumed in Australia, the Unit-
ed Kingdom and Canada than any other opioid 
(1). In Australia, this includes codeine-contain-
ing analgesics such as codeine with ibuprofen 
(e.g. Nurofen Plus®) that are available without 
a prescription, and those such as codeine with 
paracetamol (e.g. Panadeine Forte®) that are 
prescription only. The analgesics available only 
with a prescription tend to have greater amounts 
of codeine in them. 
GENERIC NAME BRAND NAME
Aspirin and codeine Aspalgin®, Codral Cold 
& Flu Original®







Mersyndol® and Mersyndol 
Forte®, Panalgesic®
Table 2 Codeine, generic and brand names
Codeine-related deaths are increasing as 
the consumption of codeine-based products 
increases (2). From 2000 to 2009, deaths where 
Pharmaceutical drugs causing the most harm 
codeine was determined to be an underlying 
cause more than doubled from 3.5 per million 
to 8.7 per million population (2) (see Figure 1). 
This is about half the number of deaths related 
to Schedule 8 drugs, which include heroin (2). 
Schedule 8 drugs are drugs of dependence  
and are closely monitored. 
Dependence on codeine is also increasing. 
Public alcohol and drug clinics reported a 
fourfold increase in the number of treatments 
where codeine was a drug of concern between 
2003–04 to 2013–14 (23).
Oxycodone and fentanyl are 
other pharmaceutical opioids 
commonly misused. 
There were 806 oxycodone-related deaths 
between 2001 and 2011, including a seven-fold 
increase between 2001 to 2011 (see Figure 1) 
(28). More than half of oxycodone deaths were 
caused by a combination of drugs, while a mi-
nority were due to oxycodone toxicity alone (28). 
Fentanyl-related deaths also increased overall 
between 2000 and 2012 (4).
Figure 1 Rate of pharmaceutical opioid-related mortality in Australia, 
2000–2012. Calculated from reporting on codeine (1), oxycodone 
(28) and fentanyl (4).
Rate of pharmaceutical opioid related mortality 
in Australia, 2002–12
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Codeine (calculated from data 
reported by Roxburgh et al. 2015) 
Oxycodone (calculated from data 
reported by Pilgrim et al. 2014)
Fentanyl (calculated from data 
reported by Roxburgh et al. 2013)
Key




Fentanyl transdermal patch Durogesic®, generic 
brands
Fentanyl lozenge/lollipop Actiq®
Fentanyl IV injection Sublimaze®







For some people, medically supervised 
use of pharmaceutical drugs may be 
the most appropriate approach to 
support their health needs, particularly 
if their physical or mental pain is acute 
and likely to be short-lived. 
However, there is growing acknowledgement 
that other strategies are viable options that 
should be explored when reviewing a person’s 
need for support for chronic pain, stress,  
anxiety or insomnia. 
A number of national strategies have been 
developed that seek to reduce the use of 
pharmaceuticals and promote options for 
alternative treatments, including the National 
Pain Strategy and the National Mental 
Health Strategy referred to on page 40.  
These strategies work as multi-disciplinary 
models of care that take into account the 
physical, psychological, social and environmen-
tal factors that influence the condition, as well 
as how this care should be implemented. 
The main alternatives for anxiety, insomnia, 
stress and chronic pain are:
  Counselling, especially cognitive 
behavioural therapy
  Relaxation and mindfulness techniques
 Exercise and physical therapy
 Changes to diet and lifestyle
Cognitive 
behavioural therapy 
Cognitive Behavioural Therapy (CBT) is 
particularly effective for managing anxiety 
and insomnia (29), and can also help with stress 
management. CBT helps change unhelpful hab-
its of thinking, feeling and behaving (30), which 
in turn reduces negative thoughts and feelings, 
and restores a sense of control.
There are many different kinds of CBT, but it 
generally draws on learning, practical tools 
and training. CBT can be accessed through 
counselling, group education sessions, and 
self-help materials (29). Online platforms are a 
promising strategy for reaching and supporting 
people with anxiety and depression who might 
not otherwise receive help (31).
CBT involves the following techniques:
 Structured problem solving
  Learning to change thinking 
(e.g. identifying incorrect beliefs)






Chronic pain is identified as an issue of the 
central nervous system, but one that can be 
‘reprogrammed’ (56). There is evidence that CBT 
may therefore be useful for the practical man-
agement of chronic pain (32).
There is a specific type of CBT (CBT- I) that has 
been developed for insomnia, and consists of 
stimulus control, sleep restriction, relaxation 
techniques, cognitive therapy and sleep 
hygiene education (33). 
What’s the issue?
A 28-year-old woman, on the advice of her 
general practitioner, reluctantly agreed to see 
a psychologist because of difficulty sleeping. 
Her insomnia had led to tiredness and irritabil-
ity, and she had wanted the quick solution of a 
prescription for sleeping tablets. 
The solution
The psychologist took her through a number of 
strategies to deal with her insomnia. Beginning 
by explaining that bedtime thought patterns, 
such as worrying about what needed to be done 
the following day, can cause anxiety and frus-
tration that prevent sleep. 
Realising that she often worries at night about 
paying her bills and finding a job that suits her 
hours given she has a small child, she was more 
open-minded to addressing the root cause  
of her insomnia. 
The psychologist taught her to use a sleep diary 
to record her worries and plans for the following 
day, as well as write down any concerns that 
might arise during the night. The psychologist 
advised her to practise relaxation techniques 
including deep breathing and muscle relaxation 
throughout the day and early evening, as well as 
to remove television and computer screens from 
her bedroom. 
The woman felt like she had the tools to start tak-
ing control of her insomnia, and that confidence 
made her feel calmer before bed.
The impact
When returning to her general practitioner the 
woman reported doing well. Although she still 
struggles with sleeplessness occasionally, with 
practise she had trained herself to identify the 
thought patterns that resulted in insomnia. That 
recognition meant she especially focussed on 
her relaxation techniques during the day when 
she spotted those thought patterns returning. 
Overall, she reported lower levels of stress and 
a greater enjoyment of the time with her child, 
friends and family.
What’s the issue?
 21-year-old man felt like quitting his first job 
because he was finding it too stressful. He was 
afraid that he had developed a mental illness, 
but was ashamed that he might be ‘crazy’ and 
was also worried about the cost of seeing a 
specialist. His girlfriend encouraged him to see 
his GP who suggested he try an evidence-based 
mental health online tool. 
The solution
After completing an assessment and learning 
he was experiencing anxiety, he decided to 
complete one of the short online courses the 
site offers. The young man learnt to identify the 
deep-held beliefs that were causing his anxiety, 
including that he would make a big mistake at 
work and get fired. He was shown how to look at 
the evidence to help weigh up what the likeli-
hood was that this would happen. Given he was 
receiving more positive than negative feedback 
from his manager and colleagues, the chanc-
es of him losing his job were low. He was also 
encouraged to think about what would happen 
if he did lose his job, and came to realise this 
would just mean he’d have to find another one, 
which wasn’t a life or death situation. 
The young man also learned to identify the 
bodily changes he experienced when he felt 
like resigning from his job, such as difficulty 
breathing and a rapid heartbeat, as the physi-
cal symptoms of anxiety. The course taught him 
simple relaxation techniques like tensing differ-
ent bodily muscles for a count of 10, then slowly 
releasing them and allowing the muscles to relax 
(progressive muscle relaxation), and how to shift 
attention to the present moment to observe the 
thoughts and feelings that come to mind without 
reacting to them (mindfulness). He also down-
loaded the recommended mindfulness app.
The impact
The young man practised the relaxation and 
mindfulness techniques whenever he had 
anxiety, and started to experience less severe 
symptoms. His sleep also improved. The tech-
niques helped him deal with his anxiety when it 




Online mental health  
tool for anxiety
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Case study 1 Case study 2 
March  2017
What’s the issue?
A 30-year-old elevator technician had repeated-
ly injured his knee playing basketball. After each 
injury he had taken codeine and seen a physio-
therapist. However, he still felt pain a few months 
after his last injury and wanted it to stop so he 
could work more easily, so he visited his general 
practitioner. The doctor explained that painkillers 
are not successful at treating chronic pain. He 
wanted to refer the man to a psychologist. The 
man resisted, not understanding why he would 
see a psychologist for a problem with his leg.
The solution
The general practitioner followed three steps 
to help convince the man to see a psychologist. 
Step 1. Ask ‘why?’ 
The doctor asked the man why he felt so strong-
ly about not seeing a psychologist. The man 
explained the he thought psychologists were 
for people with mental health issues. He was just 
concerned about completing a big upcoming 
project at work, and getting rid of the knee pain  
would help.
Step 2. Motivational interviewing
The doctor used motivational interviewing 
techniques and asked about the man’s stress 
levels to foster a discussion about the negative 
impacts that stress was having on his life. After 
discussing the frustration his pain was causing, 
and how this stress was affecting his relation-
ship, the man was more open-minded to ad-
dressing stress as an element of managing 
his pain and more likely to see a psychologist.
Step 3. Providing information and an  
option that helps
The general practitioner explained that the 
brain plays a big role in the experience of pain. 
Pain comes not from a part of the body, say a 
broken wrist, but is the result of the brain eval-
uating information such as expectations and 
beliefs, including worry and stress. The doctor 
then explained that this was where counselling, 
especially cognitive behavioural therapy (CBT), 
could help because it provides practical tools 
and training on how to reduce worry and other 
sources of stress. This could make pain much 
more manageable.
The general practitioner then explained 
that while counselling is usually a private and 
reflective conversation with a professional, CBT 
is very specific in identifying thought patterns 
and ways to change them. 
The impact
Once the doctor explained that this treatment 
is subsidised and the patient could be referred 
to a nearby psychologist, the man agreed to at 
least give it a go. He didn’t know that the brain 
influenced his pain, and wanted to learn more 
about how he could control it.
At his psychologist visit, he learned that CBT is 
a mixture of education and practical exercises 
that are normally completed in a series of steps 
that build upon the previous lesson. This includes 
learning more about the symptoms of stress and 
anxiety, why they keep happening, and how to 
identify unhelpful thoughts that influence the 
mind and body.
The physical and mental component of CBT 
involves talking and thinking in a different way 
about sources of stress, as well as muscle relax-
ation techniques and deep breathing. The man 
took home a manual with a series of lessons, real 
stories about how others have managed stress 
and anxiety, and instructions on practicing mind 
and body exercises daily.
After his psychologist visit, the man practised 
these techniques and continued to see the 
psychologist. He better understood what hap-
pens to his body when stressed (feeling hot, 
upset stomach, muscle tension) and found two 
techniques particularly helpful. When stressed, 
the man would write down a list of what needs 
to get done at work and also use deep breathing 
when he felt hot, bothered, and stressed. 
 
Although the knee pain is still there and fluctu-
ates in severity, it’s not all the time. He believes 
he’s improving, and sleeping better as well.
“  He didn’t know that the brain 
influenced his pain, and wanted 
to learn more about how he 
could control it.”
 
Preventing chronic pain through 
learning how to better manage 
stress and anxiety
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A 46-year-old woman, who had a motor vehicle 
accident as a teenager, was experiencing pain 
in her neck and shoulder. After a neurologist told 
her that it was chronic non-malignant pain, she 
became very worried that the pain might be 
causing more harm to her body. Keen to avoid 
using medication to treat it, she asked her gener-
al practitioner to explain what the ongoing pain 
meant and if it was causing more damage.
The solution
Her doctor explained that this pain condition 
didn’t mean that there was ongoing damage, 
or that she was at risk of neurological damage. 
Instead, the chronic pain is linked to the central 
nervous system. The woman felt reassured after 
the explanation because she understood that 
the pain didn’t mean more damage was happen-
ing to her neck and shoulder as she moved. 
The impact
At the follow-up appointment the woman 
told her doctor that she still felt some pain most 
days, she had been managing it with stretching, 
exercise and massage. Understanding that the 
pain was not putting her body at risk improved 




Regular physical activity can assist in improving 
energy levels, sleep behaviour, and lift moods 
(34). These benefits make exercise helpful in 
the management of anxiety and depression, 
and an important component of physical and 
mental health (35). Thirty minutes of moderate 
to intense physical activity most, if not all, days 
is recommended. Although it can be especially 
difficult for those suffering from anxiety and 
depression to start exercising and stay motivated, 
beyondblue forums offer helpful suggestions. 
Exercise is beneficial for anxiety because it 
reduces inflammation and oxidative and nitro-
gen stress, which can in turn positively affect the 
brain’s ability to create new neural pathways 
(36). The management of stress may similarly 
benefit from changes in the brain as a result of 
physical exercise, but there is a need for further 
research in this area (37).
Guided physical therapy restores physical and 
emotional functioning to better manage chronic 
pain, and does this through muscle strengthen-
ing, postural training and active self-manage-
ment strategies (38).
 
Exercise and chronic pain
“  Thirty minutes of 
moderate to intense 
physical activity 
most, if not all, days 
is recommended.”
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A 55-year-old man underwent an operation for 
lower back pain and returned to work. He was 
prescribed Endone® to help with his initial return 
to work, but the prescription ran out and he’s 
continued to experience some pain over the last 
couple of months that has been distracting him 
at work. He was unable to stop working, as he 
was on a short contract, so his wife suggested 
he ask their general practitioner for a referral to 
a pain management clinic.
The solution
The doctor explained that pain management 
clinics work with patients to develop tailored 
treatment plans, ones that often involve physio-
therapy, psychology and occupational therapy 
sessions with pain specialists. He also told him 
that guided physical therapy could improve 
muscle strength, posture and self-management. 
After being referred to a pain management clinic 
in a major hospital, the man participated in a 
group pain education program. Although he 
found the pain education helpful and wanted to 
go on to develop a treatment plan, wait times 
to do so were almost two years. 
The man decided that he would pay to attend a 
private pain clinic, where he underwent treat-
ment in group sessions (hydrotherapy), as well 
as individually. He also joined a local exercise 
group where he participates in a weekly  
walking session.
The impact
Although the cost of treatment is a burden 
to him, he thinks it’s worth it because it has 
improved his life in other ways, including his 
relationship with his wife. He also enjoys being 
social with the walking group. Sometimes he 
still experiences the pain, but over time and with 
practise has learned different ways to manage it. 
Dietary changes
Diet has a direct impact on the brain and the 
rest of the body. For example, amino acids are 
required for the body to construct neurotrans-
mitters such as serotonin and dopamine, and 
omega-3 fatty acid has been linked to improved 
mental health (39) (34). 
Increasing the consumption of certain foods and 
drinks, and reducing others, can relax the body 
and reduce stress. Generally, a balanced diet 
rich in vegetables, fruits, legumes, lean proteins 
like fish, and whole grains is recommended (40). 
Reducing the intake of foods high in added sug-
ar and salt, as well as those high in saturated 
fats, can also be beneficial (40). Drinking water 
to stay hydrated throughout the day is import-
ant. Including probiotic foods such as kimchi, 
miso, sauerkraut, pickles and kombucha may 
potentially have a positive impact on mood and 
energy levels (41).  
If magnesium (which relaxes muscles), vitamin 
B and calcium are at low levels in the body, 
then increasing these can help to reduce anx-
iety symptoms (42). Reducing consumption 
of nicotine, caffeine and stimulant drugs also 
helps reduce stress as they trigger the adrenal 
gland in the body (42). Dietary supplements, like 
multi-vitamins or fish oil, may help to achieve a 
balanced diet but a doctor should always 
be consulted (43).
Research is pointing to a link between poorer 
mental health and the modern ‘western’ diet 
high in refined grains, confectionery, and take-
away foods (44) (45) (40). Almost all serotonin 
present in the blood originates in the gastroin-
testinal (GI) tract (46) and a research review 
concludes that it is now known that microbiota 
(the bacteria that live in the human GI tract) 
have an influence on ‘stress behaviours’ such as 
anxiety and depression (47). This emerging body 
of evidence indicates how crucial good nutrition 
and a well-rounded diet are to mental, as well 
as physical, health. 
Herbal supplements
There is some evidence that herbal remedies 
may help with elements of stress, anxiety and 
minor sleep disorders. For example, lemon balm 
works on receptors in the brain that trigger 
relaxation (48) and can reduce difficulty sleep-
ing (49) and green tea — which contains the 
amino acid l-theanine–f also reduces stress 
(50). However, medical advice should support 




How physical activity and 
a pain management clinic 









People who are at greatest risk of intentional 
misuse and overdose are: 
  People with complex health issues and men-
tal health problems — because they often 
take a number of different medications and 
when certain drugs are combined (especially 
opioids with benzodiazepines) the chances 
of overdose increase. If alcohol is drunk with 
these drugs this risk increases further. 
  Men in their 30s—there has been a recent 
jump in their self-reported misuse of phar-
maceuticals (20). Reasons for this have been 
identified as coping with problems such as 
depression, anxiety and rage through  
self-medication (51). 
  Women in their 40s whose level of self-report-
ed misuse has recently increased, although 
not as significantly as men (20). Women are 
prescribed benzodiazepines at twice the rate 
as men (52)— mainly for sleeping problems.
Who is at 
risk of harm? 
  People who metabolise codeine to morphine 
ultra-rapidly, which is around five per cent 
of Australians (1). These people can overdose 
after taking a small amount of codeine and 
may not be aware of the problem until after 
they have taken the drug. This is why it’s 
important to only take a low dose the 
first time codeine is used (53).
High use of dependency- 
causing medication 
People in rural and regional areas
Rural and regional areas in Australia have a 
higher consumption of over-the-counter and 
prescription drugs than in cities. This trend is 
supported by higher rates of treatment for  
dependence on pharmaceutical opioids in  
these areas (54). This may be due to the lack  
of services and alternatives to medication in 
rural Australia. 
People suffering from 
chronic pain, stress,  
anxiety and insomnia 
Anyone taking opioids or benzodiazepines is at 
risk of harm. Situations that may lead to people 
taking these drugs include accidents, other trau-
ma, surgery, developing a chronic disease, and 
anxiety or insomnia as a result of chronic pain, 
financial problems or family breakdown. 
In Australia, one in four people suffer from anx-
iety (55), one in three from insomnia (33), and 
one in five will experience chronic pain (56).
Stress
The Australian Psychological Society describes 
stress ‘as a feeling of being overloaded, wound-
up tight, tense and worried’ (57). Different types 
of stress include acute stress (stemming from a 
particular situation like a deadline or traumatic 
experience), episodic acute stress (repeated 
acute stress due to circumstances, patterns of 
thinking, or both) and chronic stress (when the 
cause of stress is ongoing and doesn’t look like 
it will end) (57). Stress can come from various 
areas of a person’s life depending on their 
individual circumstances, but the most common 
stressors for Australians are: 
01     Personal finance issues such as 
redundancy, unemployment and debt
02    Family issues including separation 
from a partner or divorce
03   Personal health issues (55)
Other general forms of stress are:
 Work stress or job change
 Change in living arrangements
  Pregnancy and giving birth,  
postnatal depression
  Caring for parents or those with a 
disability or mental health condition
  Major emotional shock following 
a stressful or traumatic event
  Verbal, sexual, physical or emotional 
abuse or trauma
 Death or loss of a loved one (55)
Anxiety
Anxiety is the most common mental health issue 
and differs from normal feelings of nervousness 
or anxiousness because it involves excessive fear 
or anxiety. Key features of anxiety disorders 
are their persistence, and they can centre on 
areas that a person may find difficult to control, 
such as work and school performance. Apart 
from anxiety and/or fear, individuals can expe-
rience ongoing physical symptoms including 
restlessness or being ‘on edge’, becoming easily 
fatigued, having low concentration, poor sleep, 
muscle tension and irritability (58).
Link between pain,  
stress and anxiety
 Stress and anxiety are also a major source 
of chronic pain including headaches and back 
problems. Around 15 per cent of Australians are 
taking pain relief for a headache at any given 
time(99). One in four Australians who experience 
stress believe it has a moderate to very strong 
impact on their physical and mental health (55). 
The combination of physical pain and mental 
health issues can lead people to take both  
opioids and benzodiazepines. This combination 
of drugs increases the risk of negative side  
effects including overdose, especiallywhen  
combined with alcohol. 
Insomnia
There are many reasons why sleep patterns  
are disrupted including stress, anxiety, depres-
sion, pain, alcohol consumption and shift work. 
While there are a range of disorders associat-
ed with sleep, the most prevalent indicators of 
insomnia are the difficulty of falling asleep or 
maintaining sleep (58).
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“ Stress and anxiety 
is also a major source 
of chronic pain including 
headaches and back 
problems.”
Who is at risk of harm?
Insomnia can fall into two categories: acute 
or short term — usually lasting less than three 
months — and chronic. In the short term, dis-
rupted sleep can lead to increased irritability, 
poor concentration and accidents, while chron-
ic insomnia can lead to depressive disorders, 
illness and reduced productivity (58). Insomnia 
appears to be more common among females 
than males and older people can find their sleep 
patterns are disrupted due to illness and/or 
medication (58).
People experiencing insomnia may be at risk of 
misusing pharmaceuticals if they are prescribed 
benzodiazepines as a treatment given this med-
ication may cause dependence (59). If a person 
continues to use benzodiazepines beyond the 
recommended short-term period of two to four 
weeks, they are at a greater risk of developing  
a dependence (25).
Pain
Chronic pain is classified as pain that continues 
for more than three months (15). This differs 
from acute pain, which occurs after surgery, 
trauma or other medical conditions and lasts 
a shorter time. Of course acute pain can 
become chronic pain. 
People with chronic pain may be more 
likely to misuse pharmaceuticals, some of the 
reasons include:
  The longer opioids are taken the higher the 
chance of dependence
  The pain, or the medication they are taking 
for it, can cause depression and anxiety (28)
  They are more likely to develop a complex 
profile of physical and mental health prob-
lems, and take a range of medications for 
a long period of time 
  They are more likely to either be experiencing 
social and economic disadvantage or 
become disadvantaged in this way due 





With the right 
information,people 
are capable of 
changing their  
behaviours for 
the better. 
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What is causing 
the problem?
Subsidy of opioids  
to treat chronic pain
The use of opioids exceeds 
the increase in reported pain 
prevalence over the past 25 
years(61).
Nearly half of Australian general practitioner 
prescriptions for opioids are to treat chronic 
pain (61), but evidence suggests these drugs 
may not be effective at treating this condition 
(14) (62). Trends in opioid consumption are  
directly linked to the subsidy of specific opioids 
by the Pharmaceuticals Benefit Scheme (PBS), 
as well as the expansion of that subsidy to  
include treatment for chronic pain (61). 
Between 1992 and 2012, the number of 
times opioids were dispensed through the 
PBS increased 15-fold to 7.5 million, and the 
corresponding cost to the Australian govern- 
ment was 32 times higher at $271 million (22). 
High rates of anxiety, 
stress and insomnia
According to an annual survey conducted by  
the Australian Psychological Society, many 
Australians report high levels of psychological 
problems. One-third report a significant level  
of distress in their lives, one-quarter report  
moderate to severe levels of symptoms of  
depression, while one-quarter report above  
normal levels of anxiety symptoms (55).
While benzodiazepine dispensing has slightly 
decreased, prescriptions still remain at high 
levels. The quantity per script dispensed has 
increased, which means benzodiazepine can 
be used for a longer period of time, increasing 
the risk of dependence and misuse. 
Lack of alternative 
treatments
Access to mental health and pain management 
services and professionals is extremely limited, 
especially in rural and remote areas. As general 
practitioners only have short consultation times, 
this makes it difficult to get to the root cause of 
the problem and convince patients to consider 
alternatives, as well as research how to access 
these alternatives (56). 
Doctor prescribing 
patterns
The National Pain Management Strategy indi-
cates that many health professionals have limit-
ed training in pain management (63). This lack 
of training may result in general practitioners 
and other primary care prescribers defaulting to 
the prescription of pharmaceuticals to deal with 
pain when there may be other less risky and 
more appropriate long-term options available.
Patient expectations
  Although Australians may see 
medication as a ‘silver bullet’ for 
their health conditions, their problems 
are often complex and drugs can 
have side effects. 
Rather than seeking out a quick fix, 
patients need to persevere to get a correct 
diagnosis and be willing to try a variety of 
treatments and lifestyle changes. 
While evidence shows the benefits of counsel-
ling, mindfulness and relaxation practices, 
there is still a certain stigma associated with 
these treatments, which could be preventing 
people from trying these options (64). 
Over promotion by  
pharmaceutical 
companies
Controlled drugs like Oxycontin (oxyco-
done) can be abused and diverted, and when 
‘over-promoted’ and highly prescribed they cre-
ate an increased public health risk (28). In 2007, 
this became an issue for US company Perdue, 
manufacturers of Oxycontin, who pled guilty 
to misleading regulators and prescribers about 
the risks of the drug’s dependence potential for 
misuse (28) (65). 
While there has not been a similar court ruling 
in Australia, pharmaceutical company represen-
tatives do promote drug company information 
to general practitioners here (66), and this may 
shape prescribing practices. 
There have been significant increases in pre-
scribing and supply of oxycodone. The supply of 
oxycodone increased by 562 per cent between 
2001 to 2011, and there was an increase in pre-
scribing of oxycodone above any other prescrip-
tion opioid (28). This increase in prescribing led 
to increased misuse and diversion (28) (67).
September  2017 Prevention Research
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What is being 
done to address 
the issue?
National Pharmaceutical 
Drug Misuse Framework 
for Action (2012 – 2015) 
In 2010, the Ministerial Council of Drugs, through 
the Intergovernmental Committee on Drugs, 
agreed to develop a national strategic response 
to address pharmaceutical drug misuse. This 
work outlined the problem, its perspective in 
the broader policy context, and the potential 
responses governments could adopt (16).
Nine priority areas for action were identified 
and included in the National Pharmaceutical 
Drug Misuse Framework for Action (2012–2015) 
(68), driven by a focus on ‘quality use of 
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MedsASSIST 
A tool called MedsASSIST is a real-time recording 
and monitoring system for medicines contain-
ing codeine. Funded by the Pharmacy Guild of 
Australia, it is being being rolled out nationally 
(70). MedsASSIST was developed in response to 
concerns over patient safety relating to medi-
cines containing codeine. It acts as an effective 
alternative to requiring patients to visit a  
general practitioner to get a prescription for 
these products (71).
National program for 
real-time monitoring 
of prescriptions 
The Commonwealth Government has funded  
the Electronic Recording and Reporting of Con-
trolled Drugs (ERRCD) system, which is being 
developed with the Australian Digital Health 
Agency. Currently two states have decided  
to implement the program: 
Tasmania
Tasmania implemented the DAPIS Online  
Remote Access (DORA) system in 2011. DORA 
is a decision support tool for prescribers that 
provides secure, real-time access to objective 
information about:
  Supply of Schedule 8 medications by Tasma-
nian pharmacies for a particular patient
  Authorities issued to the general practitioner 
to prescribe Schedule 8 medications 
 T he patient’s history of drug dependence
 or drug seeking
  The patient’s past or current treatment 
for opioid dependence
Victoria
In 2016 Victoria announced that real-time  
monitoring would be implemented in the state.  
The system will monitor all Schedule 8  
medicines, such as oxycodone (brand names
include OxyContin® and Endone®), morphine 
(brand names include Kapanol®), alprazolam 
(Xanax® and Kalma®), methylphenidate (Ritalin®) 
and dexamphetamine, because of their high risk 
of misuse. Further consultation with professional 
medical and pharmacy groups will determine 
how best to bring into the system other high-risk 
medicines, such as diazepam (Valium®) (72). 
Rescheduling 
The rescheduling of the benzodiazepine  
alprazolam (brand names include Xanax® and 
Kalma®) to Schedule 8 was introduced in 2014, 
which means the prescribing of the drug is  
now more closely monitored.
Reformulation
 
The reformulation of oxycodone tablets to an 
abuse-deterrent, sustained-release version 
in Australia in 2014 has led to a decline of  
OxyContin® pharmacy sales and a reduction 
in OxyContin® use (8). This new formulation was 
found to successfully lower levels of misuse by 
making it harder to crush up the tablets and 
inject the medication (8).
National Opioid Substitu-
tion Treatment OST project
This project has developed a paper that anal-
yses and discusses the current listing, fee and 
remuneration arrangements of the delivery of 
the OST pharmacotherapies program. It con-
solidates issues and recommendations raised 
in previous reviews and work undertaken over 
recent years. This information is used to deter-
mine what changes, if any, will make the OST 
pharmacotherapy program more accessible, 
equitable, affordable, and effective. 
A national opioid substitution treatment 
project has been completed in Tasmania 
and is a cross-government, shared funding 
model project.
 
National Return of 
Unwanted Medicines
The National Return of Unwanted Medicines is 
a Federal Government project operating in every 
state. The national scheme provides for unwant-
ed and out-of-date medicines to be collected by 
community pharmacies from consumers. The 
medicines are then suitably disposed of by high- 
temperature incineration (74). 
NPS/MedicineWise online 
learning and fact sheets 
for health professionals
NPS/MedicineWise has developed a suite 
of resources to raise awareness of the issues 
surrounding pharmaceutical misuse, as well as 
providing practical advice to pharmacists and 
other health professionals on how to identify 
and address drug misuse and abuse. To support 
this need, NPS/MedicineWise has launched a 
new online learning course, ‘Drug misuse: impli-
cations for pharmacists’ (75) and has developed 
a large range of factsheets. 
Marketing and promotion 
of pharmaceuticals
In 2009, a paper published on OxyContin®  
highlighted how Purdue Pharma’s marketing 
campaign made OxyContin® the prescribed 
drug of choice for chronic pain. It was marketed 
as ‘less addictive and less subject to abuse and 
diversion than other opioids’. In 2007 Purdue 
Pharma was found guilty and fined millions  
of dollars for misbranding (65). 
Pharmaceutical company 
self-regulation 
Pharmaceutical companies self-regulate their 
advertising to health professionals. In 2014 the 
Australian Competition and Consumer Commis-
sion (ACCC) requested the mandatory reporting 
of all payments to healthcare professionals. As 
a result, Medicines Australia has developed a 
code of conduct (76) for its members and the 
recent edition was approved by the ACCC.
Though only members of Medicines Australia 
are required to follow the code, it sets the stan-
dard for the ethical marketing and promotion 
of prescription medicines to health professionals, 
including general practitioners. 
Recently, the code was amended to include 
the following additions:
  The new Code requires Medicines Australia 
member companies to publicly report when 
a company pays a healthcare professional 
for their service or provides financial support 
for a healthcare professional to engage in 
education, including airfares, accommoda-
tion and conference registration fees.
  From October 2015, all member companies 
will be required to collect and report this 
information where they have the agreement 
of the healthcare professionals who are 
receiving payments or educational support. 
Following this 12-month period of adjustment, 
from 1 October 2016, the Code will require 
reporting of all these payments to healthcare 
professionals to be mandatory.
What is being done to address the issue? 
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National Pain Strategy 
The primary goals of the National 
Pain Strategy are: 
  To destigmatise those with pain, 
especially non-cancer pain 
  To have federal and state governments 
recognise chronic pain as a disease in 
and of itself, not just as a symptom 
  To provide information and support 
for those with pain and their carers
  To train and support healthcare providers 
in best practice for pain management
The National Pain Strategy identifies pain as 
being influenced by physical, psychological 
and social factors. Because of these multiple 
influences, best practice in treatment is rec-
ognised by the strategy as multidisciplinary. 
The strategy defines five types of pain: acute, 
recurrent (e.g. migraines), sub-acute (transi-
tionary period where pain can become chronic), 
chronic non-cancer and cancer pain. It also 
emphasises the importance of treating acute 
and sub-acute pain effectively, to prevent 
it developing into chronic pain. Chronic pain 
is identified as an issue of the central nervous 
system, but one that can be ‘reprogrammed’ 
through treatments such as cognitive 
behavioural therapy.   
There has been some progress following the 
introduction of the strategy, such as the ACT 
recognising chronic pain as a disease and the 
opening of 14 pain clinics across New South 




The LIFE framework is the overarching, 
evidence-based framework for suicide 
prevention. It looks at such issues as risk and 
protective factors and how to influence them, 
as well as community and individual resilience 
in order to inform the provision of suicide 
prevention programs (83). 
Primary Health Networks have been commis-
sioned by the Commonwealth Government 
to provide regionally appropriate suicide 
prevention, with a specific focus on Aboriginal 
and Torres Strait Islander communities.
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“ Chronic pain is identified as  
an issue of the central nervous 
system, but one that can be 
 ‘ reprogrammed’ through 
treatments such as cognitive  
behavioral therapy.”
Non-member pharmaceutical companies do not 
have to follow this code, though they must ad-
here to the Therapeutic Goods Association code 
for the advertising of over-the-counter medicine 
to consumers. Advertising prescription-only and 
certain pharmacist-only medicines to the gener-
al public is prohibited (77).  
‘No advertising please’ 
campaign
In 2014 the ‘No advertising please’ campaign 
was launched worldwide, which was devel-
oped by Australian general practitioners and 
researchers. It was created to urge general prac-
titioners to avoid using drug representatives as 
their ‘educational’ resource and to pledge not to 
see them at their practice for one year. 
Primary Health Networks
The service delivery for mental health and sui-
cide prevention is undergoing a national change. 
Primary Health Networks (PHN) across the 
country are taking up the responsibility in their 
specific region for these services. 
The 31 PHNs are expected to meet the needs of 
their region by first assessing what the existing 
services are, then determining what more can be 
done for their specific community (78). 
  A ‘stepped care’ approach 
is being adopted, which 
means that the service 
level will be matched to 
an individual’s needs.
For example, a person experiencing mental 
health issues might be directed to low intensity 
treatment, which could be online. On the other 
hand, someone experiencing a severe or com-
plex mental health issue would be matched  
to a high intensity treatment (79). 
As part of the Commonwealth Government’s 
PHN strategy, which includes priority areas 
of mental health and eHealth, a Digital Mental 
Health Gateway is being developed to assist 
users to navigate services and match treatment 
to their needs. Self-help and digital services 
are intended to assist people who are at-risk or 
living with mild mental health issues, in addition 
to the ‘well’ population (79). 
This is also in line with the national E-mental 
health strategy, which identifies the importance 
of using technologies such as telephone and 
online treatments to assist in overcoming the 
obstacles of distance, stigma and cost. Treat-
ment in this manner helps to reach people not 
currently accessing services. The strategy calls 
for E-mental health to be integrated into the 
primary healthcare sector, and including it 
in the toolbox of the PHN is a realisation of 
that goal (80).
National Mental  
Health Strategy 
The Commonwealth Government is developing 
an updated National Mental Health Strategy 
due to be completed in 2016 (81). It will follow on 
from the fourth National Mental Health Strategy, 
which set the following goals:
 Reduce the stigma surrounding mental illness
  Improve links between mental health services 
and other programs such as education, 
housing and employment
  Adopt a ‘recovery philosophy’ that  
recognises that by managing a mental 
health problem, a person can reach their  
full potential (82).
What is being done to address the issue? 
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Health literacy 
There is an ongoing need to  
increase Australians’ health  
literacy to help people take  
medication safely.
Health literacy is the ability of people  
to understand and apply information about  
health in their daily lives—as individuals, and in  
health system environments (84).
“  In Australia, 60 per cent of adults  
have low individual health literacy,  
and low health literacy has been  
consistently associated with poor  
health outcomes (85).”
Low health literacy can make understanding information  
about medication difficult. 
“  Warning labels on medicine packs, 
such as ‘Don’t mix this medication 
with alcohol’, should be included.”
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Awareness raising
Pharmaceutical drugs are not a panacea for 
healthcare issues. We should all be aware of 
the side effects of our medication, so we can 
make good decisions based on this information. 
Seeing healthcare professionals who let you 
ask questions about your care is a crucial part 
of taking responsibility for your health, getting 
a correct diagnosis and receiving the best 
treatment.  
To help people better understand and share 
their healthcare decisions (86) involving 
pharmaceutical drugs, the Alcohol and Drug 
Foundation recommends the following key 
messages for patients:  
  When medications like codeine and Valium® 
are used regularly for a long time, the 
negative side effects can often outweigh 
any positive effects.
  Strong pain relief like codeine should only  
be used for a short period of time. They can 
stop working if they are used for too long  
and have serious side effects including 
dependence. Try to switch to paracetamol  
as soon as possible, but consult with your  
healthcare professional.  
  The side effects of strong painkillers like 
codeine include drowsiness, constipation, 
reduced sex drive and fertility, dependence, 
muscle tension, headaches, dental and 
stomach problems, moodiness, fluid  
retention and decreased bone density. 
  There are better treatments for stress, 
anxiety and insomnia than medications 
such as Valium®.Eating a well -balanced 
diet, exercising regularly and getting 
counselling (either online, over the telephone 
or in person) is not only proven to be more 
effective at treating these conditions, they 
also don’t have negative side effects. 
  Medication like Valium® should not be taken 
for longer than two weeks. It can cause 
dependence, reduced sex drive, fertility 
problems, depression, headaches, fatigue, 
difficulty sleeping, irritability, personality 
changes, impaired thinking, paranoia and 
clumsiness.
  Reduce your chances of negative side effects 
or overdose by never mixing medication such 
as Valium® with alcohol. 
  Ask your doctor or pharmacist about the side 
effects of any medication you are taking to 
make sure you will still be fit to do activities 
like driving, working or looking after children.  
  If you want to restart taking a medication, 
consult with your doctor first rather than 
using leftover drugs. 
  Don’t share medication with family or 
friends. There is no safe level of drug use.  
It is important to be careful when taking  
any type of drug. 
 The number of people overdosing on    
 medication like codeine has increased   
 significantly recently.
Information about side effects should also be 
made consistently available on pharmaceutical 
packs or in them. Warning labels on medicine 
packs, such as ‘Don’t mix this medication with 
alcohol’, should be included. At the moment, 
it’s often up to doctors or pharmacists to 
communicate this information to patients. 
Information with medication packs would 
give doctors or pharmacists a readily available 
resource to use for these conversations and help 
patients remember what they have been told.
What  






What can health 
professionals do?
There are practical steps that health 
professionals can take to prevent further harm 
from pharmaceutical drugs with the people 
they support and in their work for agencies.
Basic steps for health professionals 
to take include:
01   Better understand drugs like opioids and 
benzodiazepines including appropriate 
and inappropriate use, and their side ef-
fects.
02   To help identify patients suffering from the 
side effects of medication, ask them about 
their daily lives. For example, “Have you 
had trouble remembering things?”, 
 “Do you ever feel dizzy or tired at work?”.  
   Given the stigma attached to drug 
dependency asking a patient outright 
about their drug consumption may often 
not be a successful line of questioning. 
03  Check whether pharmaceutical drugs 
can be managed differently. For example, 
are the drugs part of a health plan that is 
reviewed periodically? Do the drugs need 
to be used at all?
04  Understand alternative treatment and 
develop ways of explaining the benefits 
of them to patients.
05  Refer to specialists where required, i.e. 
pain clinic, headache clinic, psychologist, 
dietician, and/or physiotherapist.
Early intervention 
Healthcare professionals should attempt to 
intervene before pharmaceutical drugs become 
a problem. A patient might, for example, experi-
ence one or more of the following situations: 
  They’re about to have surgery and  
experience acute pain.
  They recently had an accident or  
experienced another trauma.
  They’re experiencing troubles related  
to anxiety or difficulty sleeping. 
  They might have a history of drug  
(including alcohol) dependency.
  They’re experiencing headaches, muscle 
soreness and/or other bodily pain.
  They experience work and/or family related 
issues that may increase risk of anxiety, 
trouble sleeping and/or physical pain.
  They may be less well-connected socially, 
be without strong social support networks, 
be facing employment challenges (includ-
ing underemployment or casual/unstable 
employment), lack adequate housing and/
or have low health literacy. 
When they understand the patient’s situation, 
healthcare professionals can provide appropri-
ate information on how to manage pain, stress, 
anxiety or insomnia without relying on medi-
cation long term. Where appropriate, they can 
provide information on the risks involved with 
using these drugs for extended periods of time, 
while still supporting those in their care.  
Supporting better practice
Healthcare professionals can find the relevant 
contact for policy and practice guidelines on 
medicines at their agency (e.g. Policy Officer, 
Clinical Leader) and discuss how to adapt 
practice-wide policies on safe opioid and ben-
zodiazepine prescribing. One option is to use 
a recommended prescribing template, such as 
‘Prescribing drugs of dependence in general 
practice, Part A’ on the Royal Australian College 
of General Practitioners’ website. 
Health professionals should also do supplemen-
tary training in pain management and addiction 
medicine, given the high use of these drugs in 
Australia. There is accredited online training 
available through institutions such as the Royal 
Australian College of General Practitioners.  
Primary Health Networks
Primary Health Networks can facilitate educa-
tion and training for general practitioners and 
allied health practitioners in their local area and 
also provide consumer education. They can also 
facilitate community support groups for con-
sumers and provide access to online information.
Due to the high rates of medications with  
dependence potential being prescribed in rural 
and remote areas, there is a specific need to 
provide tele-health facilities, including multi-dis-
ciplinary pain management teams in primary 
care. Incentives for general practitioners and 
other health professionals to do training in pain 
management and to use tele-health is needed. 
“  Health professionals should 
also do supplementary 
training in pain management 
and addiction medicine, given 
the high use of these drugs 
in Australia.”
What else can be done? 
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What can parents do?
Parents are a target audience of the Alcohol and Drug Foundation, 
given the key role that they can play in preventing alcohol and other 
drug problems. Parents are the first ‘drug educators’ their children 
know and parental use of drugs, including medication, is understood 
as a powerful model for their children’s behaviour.  Research indicates 
that children grow up to imitate their parents’ attitudes and behaviours 
towards drugs (87). 
Safe use of medication 
When children are in pain, it’s natural for 
parents to want to relieve their suffering. 
However, there is some important information 
that parents need to know:  
  Children under the age of 12 should not be 
given over-the-counter codeine (88) or any 
product containing codeine.
  Aspirin should never be given to children 
under 16, because it’s associated with a rare 
but serious disease called Reye’s Syndrome, 
which can cause delirium and coma (89).
  Paracetamol is the most common over-the-
counter medicine associated with uninten-
tional overdose requiring hospitalisation in 
children less than five years of age (90).
  Parents should weigh their children to avoid 
overdosing them with medication (90).
  It’s important to read the label and medical 
information and find out what is in the 
medicine, especially the main ingredient.
 
  All medicines should be safely stored  
away from children. 
  Pain relief medications mask pain, they don’t 
reveal the cause. So, it’s important to find 
out what is causing the pain. 
Dealing with pain 
Parents need to consider whether pain medica-
tions really need to be used when their child is in 
pain. If medication is given, then parents should 
explain that they are using it as a last resort. 
There are many different approaches parents 
can take instead of using a painkiller, unless 
their child experiences severe pain, in which 
case they should be taken to the doctor. 
Some tactics to use instead of a painkiller are:
  Icepacks or heat treatments, depending 
on what’s causing the pain 
  Exercising, and by not reaching for a pill  
at the first sign of discomfort
  Distraction through games
  Ask the child’s doctor for advice
Coping strategies  
for stress and anxiety 
Equipping a child with coping strategies and 
habits from a young age can benefit them for 
the rest of their life. For example, talking about 
feelings with a child can help them manage 
their emotions. By assisting them to label 
and describe the emotions they’re experiencing, 
parents can help them understand and control 
what they feel. Parents are also emotional role 
models, and can help by demonstrating positive 
behaviours such as admitting to their own 
mistakes, apologising, and showing their child 
how to reconcile with someone they’ve hurt (91).
Parents can also create emotional stability 
in their child’s life through being personally 
consistent and predictable, and following 
bedtime and mealtime routines (93). 
  Giving children emotional skills can 
help them deal with future problems 
successfully, like the stress of exams 
or bullying in school,
through being able to identify, manage, and 
speak about their emotions. Having a history 
of comfort with talking about their feelings 
may make it more likely that they will express 
when they are worried, anxious, or unhappy 
and ask for help.
Prevention Research
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What can workplaces do?
Given work and finance troubles are listed 
among the top causes of stress and anxiety in 
Australia, workplaces need to recognise 
the opportunity they have to prevent their em-
ployees from suffering from these conditions. 
  Employers also need to know that 
the side effects of opioids and 
benzodiazepines, which are being 
widely taken in this country, can 
impact on the safety and culture  
of their workplace.
These side effects include reduced alertness and 
concentration, clumsiness, sleepiness, memory 
problems, irritability, moodiness and depression. 
The focus for workplaces should be on prevent-
ing employees from developing problems with 
these drugs, although there is also a need to 
address misuse.
Create and promote a policy 
The Alcohol and Drug Foundation advises all 
workplaces to have a formal alcohol and other 
drug policy that includes the use of over-the-
counter and prescribed medications. 
A comprehensive workplace policy enables an 
organisation to meet its duty of care obligations 
under the workplace health and safety legisla-
tion that requires employers to provide a work-
ing environment that protects the health and 
safety of its workers. 
An effective policy provides strategies that will 
assist managers to prevent alcohol and drug 
problems from happening and provide guidance 
to help deal with difficult situations if and when 
they arise. 
To be effective, policies also need to be known 
and understood by every employee throughout 
the workplace. This can be achieved through 
regular and ongoing education, including 
talking about the policy and the risks associated 
with alcohol and drug misuse. 
Through the policy, employees who are taking 
medication should be encouraged to inform 
their manager of any limitations placed on them 
as a result of taking the drug, including getting 
a letter from their doctor to excuse them from 
their normal duties. Workplaces need to try and 
accommodate this person with alternative duties 
so they can follow their doctor’s advice while 
also working safely. Employees need to under-
stand that the responsibility sits with them to 
check with their doctor or pharmacist about the 
possible side effects of any medication they are 
taking and how it might impact on their work.  
Improve health and wellbeing 
A key aspect of preventing pharmaceutical 
drug misuse is equipping employees with the 
knowledge and tools they need to maintain 
good mental health.
Workplaces can encourage their employees to:
 
  Use employee assistance programs and  
other free counselling options, and reduce 
the stigma that is attached to accessing 
these programs.
  Eat well-balanced meals, including making 
sure there are healthy lunch and snack op-
tions, and providing education about nutri-
tion and its link to mental health.
  Do regular exercise through encouraging 
walking meetings, providing shower facilities 
and bike storage, organising exercise classes, 
and providing education on mental health. 
  Establish good sleeping patterns, including 
discouraging excess overtime and providing 
education around how to maintain good 
sleep patterns. 
  Reduce the use of alcohol and other drugs, 
by providing education about the harms of 
these substances and ensuring alcohol isn’t 
the focus of workplace functions. 
“  Workplaces need to try and 
accommodate this person with 
alternative duties so they can 
follow their doctor’s advice 
while also working safely.”
Prevention Research
There are details of free and confidential 
services that can support people to improve 
their mental health, which workplaces can 
promote, in the ‘Resources’ section of this 
publication on page 58. 
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What can communities do?
Community groups and organisation can play 
a vital role in preventing mental health and sub-
stance misuse problems, and are a key target 
audience of the Alcohol and Drug Foundation. 
While this publication has identified some 
Australian-wide trends, communities are in the 
ideal position to understand what the key issues 
are in their local area that might be causing 
harms from pharmaceuticals. 
To help prevent these problems communities can:
  Create opportunities for people to connect 
to others and develop a purpose in life, which 
are two key ways to help prevent mental 
health and substance misuse problems. 
  Organise and promote opportunities for  
people to relax, engage in mindful practices 
and exercise. 
  Make sure there is a wide range of healthy 
foods available in the community, and help 
increase people’s understanding of what a 
well-balanced diet looks like and how it can 
affect mental health. 
  Raise awareness of the side effects of opi-
oids and benzodiazepines and alternative 
treatments, through libraries, neighbourhood 
houses, sporting clubs, men’s sheds, maternal 
and child health services and local media.  
  Provide information in different community 
languages to target minority populations. 
 
  The Alcohol and Drug Foundation 
encourages communities to follow 
its ‘Six steps to planning community 
alcohol and drug projects’ whenever 
they are developing a program. 
The guide encourages community groups to 
make sure they consider promoting existing 
resources (see page 58) and understand what 
work is already happening that they can link 
into. In this case, it would be especially import-
ant to talk with the local primary health network. 
The Pharmaceutical Society of Australia may 
also be interested in being involved in a local 
awareness raising campaign.
Sporting clubs
Given there has been a significant increase in 
men in their 30s misusing pharmaceutical drugs, 
community sporting clubs provide a good place 
to promote harm reduction messages around the 
use of medication. People who play sport may 
use prescribed and over-the-counter medica-
tions, anti-inflammatories and other pharmaceu-
ticals to help them recover from injuries. 
  Some players or athletes may take 
pain relieving medications to help 
them continue to play or work while 
injured. 
Clubs have a duty of care to make sure they 
create a safe and healthy environment for their 
members. The side effects of some medications 
can affect this environment. Clubs can help 
prevent problems caused by pharmaceutical 
drugs by: 
  Encouraging injury prevention 
through appropriate warm up and 
warm down exercises.
  Discouraging players or athletes from 
playing or competing when they are injured 
to avoid the risk of further injury and exces-
sive use of medication.
  Encouraging players or athletes to get 
and follow medical advice when injured.
  Discouraging players or athletes from  
over and inappropriate use of opioids and  
benzodiazepines by promoting alternatives 
to pharmaceutical drugs for chronic pain, 
stress, anxiety and insomnia.
“  ...a community club’s policy 
on medication should be 
aligned with the club’s code 
of conduct and other health 
and wellbeing policies.” 
The Australian Institute of Sport recommends 
that sporting organisations have a written 
medication policy that is approved by a medical 
practitioner and governs the use of prescrip-
tion and over-the-counter medications. While 
community sports clubs have less control over 
the use of medication by players and athletes 
than professional and elite sports bodies do, a 
community club’s policy on medication should 
be aligned with the club’s code of conduct and 
other health and wellbeing policies. 





Conclusion Among the most serious issues is the evident overuse of opioids and benzodiazepines.  This overuse is responsible for high rates of  
drug dependency and overdose. Unnecessary 
use of these drugs creates serious problems  
for individuals, their families, and the wider com-
munity, and places additional burdens  
on the health system. 
Many Australians are unaware of how they 
may be misusing or overusing pharmaceuticals 
and of the risks involved. 
To initiate change, Australians first need to 
understand the problem and its associated 
harms. No one takes a pharmaceutical drug 
to make matters worse, yet this is a too- 
common outcome. Social marketing campaigns, 
similar to the effective and successful road 
safety campaigns, are required to ensure 
safe pharmaceutical use becomes a top 
priority for the public. 
A campaign theme should encourage adults 
to take a proactive interest in their health  
and ask questions of health professionals  
about the health impacts of medications  
and possible alternatives. 
General practitioners and pharmacists alike can 
contribute by offering the alternative treatments 
and by ensuring patients are not unnecessarily 
prescribed medications for long periods. 
Pharmaceutical companies have an obligation 
to market their products in a responsible way, 
without promising or offering exaggerated 
benefits to health professionals or consumers. 
All research and clinical trials should be made 
available for public viewing. 
Prescribing guidelines, alternative pain man-
agement treatments, and other practical tools 
and approaches can be employed to make a 
meaningful improvement to many people’s lives. 
Real time monitoring of prescriptions has at 
least begun in some jurisdictions, but it needs 
to be a national approach. 
Non-pharmacological solutions for chronic 
pain, stress, anxiety and insomnia deserve 
to be included in health benefit schemes 
and be regulated, based on the latest and 
best evidence. Particular emphasis needs to 
be on providing these options for people in 
rural and remote areas where prescription 
rates and harms for opioids and benzodiaze-
pines are at the highest. 
At a policy level, a national pharmaceutical 
strategy would help guide planned and 
comprehensive action on pharmaceutical 
drugs, and complement the National Drug 
Strategy alongside the specific plans for 
alcohol, tobacco and illicit drugs.  
More research into pharmaceutical use is 
needed urgently. We need to better under- 
stand why the cohorts of males in their 30s 
and females in their 40s are increasingly 
misusing pharmaceuticals in order to ensure 
we can develop appropriate preventative 
programs for these groups. 
With the right information, people are 
capable of changing their behaviours for the 
better. Australians have changed their road 
behaviours in response to a dedicated effort 
by various stakeholders. We can be confident 
that Australians will adopt a healthier use of 
pharmaceutical drugs when they are informed 
and fully-resourced, and when health system 
stakeholders work together to achieve that goal.
Pharmaceutical drug use in  
Australia demands urgent attention. 
Most people would be surprised to learn 
that pharmaceutical drug deaths are  
overtaking the national road toll. 
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Resources References
Understanding the safe use of pharmaceuticals 
•  Fact sheets on variety of drugs — 
Alcohol and Drug Foundation’s DrugInfo website
•  Resources for workplaces — 
Alcohol and Drug Foundation’s website
•  National Return of Unwanted Medicines 
—a Federal Government project operating 
in every state and territory
•  Fact sheets for pharmacists —NPS/MedicineWise 
•  Online learning course: ‘Drug misuse: implications 
for pharmacists’ —NPS/MedicineWise
•  Choosing Wisely: Five questions to ask your doctor 
or other healthcare provider —NPS/MedicineWise
Pain
•  New guidelines for pain assessment and management  
—Faculty of Pain Medicine 
•  Tools for pain assessment and management including 
reducing opioids —NSW Health 
•  Safer use of opioids, including for managing pain — 
Department of Health and Human Services and NPS/
MedicineWise
•  Pain and the role of medications — 
Pain Management Network
•  The Pain Toolkit —self-management techniques 
developed by someone suffering from chronic 
pain and supported by doctors
•  Chronic headache and migraine diaries — 
Headache Australia
•  Understanding Pain: What to do about it in less 
than five minutes —Brainman YouTube video
Food and diet
•  Healthy eating for people with depression, 
anxiety and related disorders —beyondblue
Anxiety, insomnia and stress
 Guides and fact sheets:
• Fact sheets on insomnia —Sleep Health Foundation
•  Benzodiazepines: Reasons to stop and stopping 
use —Drug and Alcohol Services South Australia
•  Mediated treatment plan: reduction plan for 
your sleeping tablets —NPS/MedicineWise
•  Better Sleep: How to overcome sleeping 
problems —Reconnexion
• About anxiety —Reconnexion
• A guide to what works for anxiety —beyondblue
• Man Therapy Mind Quiz —beyondblue 
 Online support:
•  ReachOut Breathe: helps reduce physical symptoms 
of stress and anxiety by slowing down heart rate 
with mobile phone or Apple Watch —ReachOut
•  MindSpot Clinic: free online assessment tool and  
treatment course, referral to other services —run 
by 30 psychologists, based at Macquarie University, 
Sydney, and funded by the Australian Government.
•  MoodGym: online learning of cognitive behaviour 
therapy skills —National Institute for Mental 
Health Research
•  Life Flex: online and mobile program that pays equal 
attention to biology, emotions, thoughts, behaviours 
and wellness levels —Centre of Biopsychosocial and 
eHealth Research & Innovation
•  Counselling Online — Turning Point, funded by 
the Australian Government’s Department of Health
Look out for new  
resources coming soon adf.org.au
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